Tailored Treatment of Patients With Hepatocellular Carcinoma With Portal Vein Invasion: Experience From a Multidisciplinary Hepatobiliary Tumor Program Within a NCI Comprehensive Cancer Center
from Journal of Gastrointestinal Oncology
BACKGROUND: Hepatocellular carcinoma (HCC) with portal vein invasion (PVI) has a poor prognosis with limited treatment options. Intra-arterial brachytherapy (IAB) and transarterial chemoembolization (TACE) yield local control but risk accelerating liver dysfunction. The outcomes, survival, and safety of selective liver-directed treatment are reported. METHODS: Thirty-seven consecutive patients with HCC and PVI treated between 2009 and 2015 were reviewed from a prospectively collected database.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063